Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

China flag China · Delayed Price · Currency is CNY
50.90
+0.59 (1.17%)
At close: Feb 27, 2026
Market Cap23.65B +35.8%
Revenue (ttm)607.75M +56.0%
Net Income-867.44M
EPS-2.00
Shares Out464.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,402,720
Average Volume2,349,202
Open50.31
Previous Close50.31
Day's Range49.56 - 51.03
52-Week Range42.40 - 86.18
Beta0.09
RSI28.81
Earnings DateMar 31, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. The company was founded in 2017 and is based in Shan... [Read more]

Sector Healthcare
Founded 2017
Employees 985
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688192
Full Company Profile

Financial Performance

In 2024, SHA:688192's revenue was 359.90 million, an increase of 294.24% compared to the previous year's 91.29 million. Losses were -845.96 million, -23.63% less than in 2023.

Financial Statements